These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 34657885)
1. Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. Liu H; Lutz M; Luo S; J Alzheimers Dis; 2021; 84(3):1323-1335. PubMed ID: 34657885 [TBL] [Abstract][Full Text] [Related]
2. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
3. Polygenic effects on the risk of Alzheimer's disease in the Japanese population. Kikuchi M; Miyashita A; Hara N; Kasuga K; Saito Y; Murayama S; Kakita A; Akatsu H; Ozaki K; Niida S; Kuwano R; Iwatsubo T; Nakaya A; Ikeuchi T; ; Alzheimers Res Ther; 2024 Feb; 16(1):45. PubMed ID: 38414085 [TBL] [Abstract][Full Text] [Related]
4. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM; Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566 [TBL] [Abstract][Full Text] [Related]
5. Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease. Li H; Liu H; Lutz MW; Luo S; J Alzheimers Dis; 2023; 91(3):977-987. PubMed ID: 36530083 [TBL] [Abstract][Full Text] [Related]
6. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453 [TBL] [Abstract][Full Text] [Related]
7. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment. Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K; Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370 [TBL] [Abstract][Full Text] [Related]
8. The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease. Femminella GD; Harold D; Scott J; Williams J; Edison P; J Alzheimers Dis; 2021; 79(1):127-139. PubMed ID: 33216025 [TBL] [Abstract][Full Text] [Related]
9. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals. Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD J Alzheimers Dis; 2023; 94(4):1587-1605. PubMed ID: 37482996 [TBL] [Abstract][Full Text] [Related]
10. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
11. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. King-Robson J; Wilson H; Politis M; J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079 [TBL] [Abstract][Full Text] [Related]
12. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
13. Genetic Association Between Epigenetic Aging-Acceleration and the Progression of Mild Cognitive Impairment to Alzheimer's Disease. Liu H; Lutz M; Luo S; J Gerontol A Biol Sci Med Sci; 2022 Sep; 77(9):1734-1742. PubMed ID: 35797594 [TBL] [Abstract][Full Text] [Related]
14. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease. Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E; Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747 [TBL] [Abstract][Full Text] [Related]
15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601 [TBL] [Abstract][Full Text] [Related]
16. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease. Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228 [TBL] [Abstract][Full Text] [Related]
17. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094 [TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. Podhorna J; Krahnke T; Shear M; Harrison JE; Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215 [TBL] [Abstract][Full Text] [Related]
20. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB; J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]